Royalty Pharma Q4 Receipts Jump 18% to $874M, 2026 Guidance at $3.3B
Royalty Pharma’s Q4 2025 portfolio receipts rose 18% to $874 million and full-year receipts climbed 16% to $3,254 million. The company deployed $2.6 billion on royalty acquisitions, repurchased $1.2 billion of shares, raised its dividend by 7%, and forecast 2026 receipts of $3,275–$3,425 million.
1. Q4 and Full-Year 2025 Financial Results
Royalty Pharma reported Q4 portfolio receipts of $874 million, up 18% year-over-year, and full-year portfolio receipts of $3,254 million, up 16%. Royalty receipts climbed 17% to $856 million in Q4 and 13% to $3,127 million for the year, while net cash provided by operating activities reached $827 million in Q4 and $2,490 million for 2025.
2. Capital Allocation and Shareholder Returns
The company deployed $2.6 billion on nine royalty transactions, including a Phase 3 partnership for daraxonrasib, and repurchased 37 million shares for $1.2 billion (including $75 million in Q4). It also increased its quarterly dividend by 7% in early 2026.
3. 2026 Guidance and Pipeline Outlook
Royalty Pharma guided 2026 portfolio receipts of $3,275–$3,425 million, reflecting expected royalty receipts growth of 3%–8%. The company anticipates pivotal study readouts for daraxonrasib, pelacarsen and litifilimab, which could unlock additional value, and projects operating costs of 5.5%–6.5% of receipts and interest payments of $350–$360 million.